Login
$TWAV
$1.41 +$0.01 (0.71%) Close

Company Executives

Officer Age In this role Joined 2024 pay Source
Peter Holst Also a director
Chairman, President, and Chief Executive Officer
56 Not stated Not stated $502,000
David Clark
Chief Financial Officer, Treasurer, and Corporate Secretary
56 Not stated 2013 $357,000

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
4
serving now
Independent
0 of 1
stated in the proxy; 3 not stated
Average tenure
6.0 years
from year joined
CEO also chairs the board
No
Jonathan Schechter
Director Age On board Independent Committees Other public boards Pay Source
Jonathan Schechter
51 2023
2 years
Not stated
Audit Committee Compensation Committee · Chair Nominating Committee
PharmaCyte Biotech, Inc. Not stated
Peter Holst
56 2013
12 years
Not independent None stated None stated Paid as CEO
Jason Adelman
56 2019
6 years
Not stated
Audit Committee · Chair Compensation Committee Nominating Committee
Trio-Tech International Not stated
Deborah Meredith
66 2021
4 years
Not stated
Audit Committee Compensation Committee Nominating Committee · Chair
None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Nov 4, 2025
Jonathan Schechter
One of our directors, partner at The Special Equities Group
Approximately $511,000
March 2023

Cash placement agent fee and warrants granted to SEG for the March 2023 Series F Preferred Stock private placement

With The Special Equities Group, a division of Dawson James Securities, Inc. Open in proxy
Jonathan Schechter
One of our directors, partner at The Special Equities Group
Approximately $206,000
April 2023 to December 31, 2024

Cash fees paid to SEG at 8% of gross proceeds from exercise of Series F Preferred Warrants and Common Warrants

With Dawson James Securities, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support